BioSpace News Archive

Innovent Biologics, Inc. announces that BYVASDA®, a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration of China for the treatment of adult recurrent glioblastoma, which is the third approved indication of BYVASDA® in China.

InnoCare Pharma, a leading biopharmaceutical company, announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia /small lymphocytic lymphoma, and the treatment of patients with relapsed/refractory mantle cell lymphoma.

The American Association of Nurse Practitioners® applauds the U.S. Surgeon General’s selection of Loretta C. Ford, EdD, RN, PNP, NP-C, CRNP, FAAN, FAANP, as the recipient of the Surgeon General’s Medallion.

Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor BRUKINSA® (zanubrutinib) are included in the NRDL in a total of four approved indications

Gannex, a wholly owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announces dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor agonist, in a U.S. Phase I Trial.